期刊文献+

利培酮与奥氮平对精神分裂症急性期的疗效及临床影响因素的比较 被引量:11

Comparison of curative effect and clinical influence factors of risperidone and olanzapine in the treatment of acute phrase of schizophrenia
下载PDF
导出
摘要 目的:比较利培酮、奥氮平治疗精神分裂症急性期的疗效及临床影响因素。方法:利培酮组27例,剂量范围2~6mg/d,奥氮平组26例,剂量范围10~20mg/d。两组均以阳性与阴性症状评定量表(PANSS)观察6周,治疗前收集患者的性别、年龄、病程,治疗中准确记录患者用药情况。结果:6周末,利培酮与奥氮平治疗精神分裂症急性期的有效率均为84.6%;奥氮平组患者在一般病理症状、阳性症状中的疗效优于利培酮组患者(P〈0.05);治疗时间长,利培酮、奥氮平治疗精神分裂症急性期的疗效增加(P〈0.05);治疗时间与利培酮、奥氮平不存在交互作用(P〉0.05);治疗时间、病程、剂量对利培酮的疗效有影响(P〈0.05),治疗时间对奥氮平的疗效有影响(P〈0.05)。结论:精神分裂症的急性期,奥氮平的疗效与利培酮相当,但奥氮平疗效的稳定性优于利培酮。 To compare the curative and olanzapine in the treatment of the acute effect and clinical influence factors of risperidone phrase of schizophrenia. METHODS: 27 caseswere treated with risperidone in a regimen of 2-6 mg/d. 26 eases were treated with olanzapine in a regimen of 10-20 mg/d. Positive and Negative Syndrome Scale(PANSS) were used to measure the efficacy for 6 weeks. The patient's gender, age, duration before treatment and accurately record the patient's drug use were collected dur ing treatment. RESULTS: The response rate at the end of 6 weeks of risperidone and olanzapine both were 84.6%. The general pathological symptoms and positive symptoms, the curative effects of olanzapine is better than those of ris peridone(P%0.05). Risperidone and olanzapine curative effects in the treatment of the acute phrase of schizophrenia were increased with theextension of the treatment time(P〈0.05). The treatment time had no interactions with risperi done and olanzapine (P〉 0.05). Treatment time, duration, dose, affected the efficacy of ris peridone(P〈0.05), treatment time affected the efficacy of olanzapine (P % 0.05 ). CONCLU SION. The curative effect between olanzapine and risperidone has no difference,but the stabli ty of olanzapine is better than it of risperidone in the treatment of the acute phrase of schizophre nia.
出处 《中国临床药理学与治疗学》 CAS CSCD 2014年第2期182-186,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 湖南省自然科学基金项目"利培酮治疗精神分裂症的个体化剂量预测模型研究"(13JJ5017) 国家"重大新药创制"科技重大专项:重大疾病新药临床评价研究综合技术平台建设(2012ZX09303014-001)
关键词 利培酮 奥氮平 精神分裂症 急性治疗期 临床因素 risperidone olanzapine schizo-phrenia acute treatment period clinical factors
  • 相关文献

参考文献13

二级参考文献62

  • 1舒畅,王高华,王惠玲,李洁,王得志.精神分裂症症状与威斯康星卡片分类测验成绩的相关性[J].中国心理卫生杂志,2004,18(8):580-582. 被引量:8
  • 2孙菊水,任列.奎硫平与利培酮治疗精神分裂症的对照研究[J].中华精神科杂志,2004,37(3):175-175. 被引量:14
  • 3汪志良,金卫东.难治性精神分裂症概念、类型及其治疗策略的认识[J].中国神经精神疾病杂志,2005,31(5). 被引量:39
  • 4陈超,吴海珊,罗有年,邓良华,刘学兵.国产奥氮平对首发精神分裂症患者的疗效及安全性研究[J].神经疾病与精神卫生,2005,5(4):306-307. 被引量:5
  • 5[1]Tollefson GD,Beasley CM,Tran PV,et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders:results of an international collaborative trial.Am J Psychiatry,1997,154:457
  • 6[2]Tollefson GD,Beasly CM,Tanura RN,et al.Blind,controlled,long-term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol.Am J Psychiatry,1997,154:1248
  • 7[3]Beasley CM,Tollefson GD,Tran P,et al.Olanzapine versus placebo and haloperidol:acute phase results of the North American double-blind olanzapine trail.Neuropsychopharmacology,1996,14:111
  • 8[4]Nemeroff CB.Dosing the antipsychotic medication olanzapine.J Chin Psychiatry,1997,58(suppl 10):45
  • 9[5]Morre NA,Tye NC,Axtom MS,et al.The behavioral pharmacology of olanzapine.A novel"atypical" antipsychotic agent.J Pharmacol EXP Ther,1992,262:545
  • 10[1]Yonkers KA, Kando JC, Cole JO, et al. Gender differences in harmacokinetics and pharmacodynamics of psychotropic medication[J]. Am J Psychiatry, 1992, 149: 587.

共引文献129

同被引文献107

引证文献11

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部